The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Much Growth In Market Value Is Expected For The Acute Care Syndromic Testing Market Between 2026 And 2030?
The acute care syndromic testing market has experienced significant expansion in recent years. This market is projected to grow from $4.59 billion in 2025 to $5.17 billion in 2026, showing a compound annual growth rate (CAGR) of 12.8%. The historical increase can be attributed to several key factors, including the demand for emergency infection diagnosis, the expansion of hospital ICUs, various outbreak preparedness initiatives, the adoption of molecular diagnostics, and the optimization of critical care workflows.
The acute care syndromic testing market is projected for significant expansion in the coming years. It is forecast to reach $8.3 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 12.5%. Key drivers contributing to this growth during the projection period include AI-enabled syndromic panels, expanded emergency testing, antimicrobial stewardship programs, point-of-care molecular systems, and an increased focus on pandemic preparedness. Significant trends anticipated over the forecast timeframe encompass rapid multiplex pathogen detection, molecular testing in emergency departments, single-sample multi-disease panels, enhanced clinical decision support speed, and a reduction in diagnostic turnaround time.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21078&type=smp
What Primary Drivers Are Shaping The Acute Care Syndromic Testing Market?
The increasing occurrence of infectious diseases is anticipated to drive the acute care syndromic testing market in the future. These diseases are illnesses resulting from detrimental microorganisms like bacteria, viruses, fungi, or parasites, which have the potential to spread among individuals, animals, or through the environment. The rise in infectious disease cases is fueled by elements such as an expanding population, increasing urbanization, international travel, resistance to antimicrobials, and changes in climate, all of which heighten the demand for effective methods of prevention and treatment. In the context of infectious diseases, acute care syndromic testing employs multiplex molecular diagnostics for swift identification of pathogens and concurrent infections, thereby facilitating precise treatment choices. For example, data from February 2024, provided by the Health Security Agency, a UK-based government body, showed that during week 4 of 2024, the influenza positivity rate rose to 16.6% from 14.0% in the prior week. Consultations for influenza-like illness (ILI) also saw an increase, reaching 9.8 per 100,000 people, an escalation from 7.5 per 100,000 in the week before. Furthermore, influenza hospitalizations ascended to 7.63 per 100,000, an increase from 5.12 per 100,000 in the preceding week. Consequently, the increasing prevalence of infectious diseases is propelling the acute care syndromic testing market.
How Is The Acute Care Syndromic Testing Market Organized By Segment Classification?
The acute care syndromic testing market covered in this report is segmented –
1) By Disease Type: Respiratory Diseases, Gastrointestinal Diseases, Genitourinary Diseases, Tropical Diseases, Other Disease Types
2) By Sample Type: Blood, Urine, Biofluids, Stool, Swabs, Other Sample Types
3) By Target: Bacteria, Viruses, Fungi, Parasites
4) By End User: Hospitals, Clinical And Diagnostic Laboratories, Research And Academic Institutions, Other End Users
Subsegments:
1) By Respiratory Diseases: Influenza, Respiratory Syncytial Virus (RSV), COVID-19, Tuberculosis, Other Respiratory Diseases
2) By Gastrointestinal Diseases: Clostridium Difficile Infection, Norovirus, Rotavirus, Salmonella, Other Gastrointestinal Diseases
3) By Genitourinary Diseases: Urinary Tract Infections (UTIs), Sexually Transmitted Infections (STIs), Vaginal Infections, Other Genitourinary Diseases
4) By Tropical Diseases: Malaria, Dengue, Chikungunya, Zika Virus, Other Tropical Diseases
5) By Other Disease Types: Meningitis, Sepsis, Other Emerging Infectious Diseases
What Trends Are Affecting The Growth Of The Acute Care Syndromic Testing Market?
Leading companies within the acute care syndromic testing market are concentrating on technological breakthroughs, such as multiplex real-time polymerase chain reaction (PCR) technology, to elevate diagnostic precision, enable swift pathogen identification, optimize laboratory workflows, reduce turnaround times, and ultimately improve patient outcomes through accurate and timely treatment strategies. This multiplex real-time PCR technology is an advanced molecular diagnostic technique that concurrently identifies and quantifies multiple pathogens or genetic targets in a single PCR reaction, thereby enhancing both efficiency and accuracy in disease diagnosis. For example, in April 2023, QIAGEN N.V., a biotechnology research company headquartered in the Netherlands, released its QIAstat-Dx syndromic testing solution in Japan. This solution incorporates a SARS-CoV-2 respiratory panel capable of detecting over 20 pathogens from a single sample. By employing multiplex real-time PCR technology, it yields rapid results with significantly less labor compared to individual PCR assays. The system is presently offered in more than 100 countries, thereby boosting the global accessibility of syndromic testing.
Who Are The Industry Participants Involved In The Acute Care Syndromic Testing Market?
Major companies operating in the acute care syndromic testing market are Siemens Healthineers AG, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Danaher Corporation, Becton Dickinson and Company, Seegene Inc., bioMérieux SA, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Werfen, DiaSorin S.p.A., Quidel Corporation, Luminex Corporation, Biocartis NV, Microbiologics Inc., QuantuMDx Group Ltd., Curetis GmbH by OpGen Inc., Genetic Signatures Ltd., Applied BioCode Inc.
Get The Full Acute Care Syndromic Testing Market Report:
https://www.thebusinessresearchcompany.com/report/acute-care-syndromic-testing-global-market-report
Which Region Accounts For The Largest Portion Of The Acute Care Syndromic Testing Market?
North America was the largest region in the acute care syndromic testing market in 2025. The regions covered in the acute care syndromic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Acute Care Syndromic Testing Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/customise?id=21078&type=smp
Browse Through More Reports Similar to the Global Acute Care Syndromic Testing Market 2026, By The Business Research Company
Tele Intensive Care Market Report 2026
https://www.thebusinessresearchcompany.com/report/tele-intensive-care-global-market-report
Severe Acute Respiratory Syndrome Treatment Market Report 2026
Tele Intensive Care Unit Market Report 2026
https://www.thebusinessresearchcompany.com/report/tele-intensive-care-unit-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model